Blood-processing devices for regenerative medicine
Pricing expected any day (our estimate) · latest SEC filing Oct 28, 2026.
Pinch-zoom for details.
RegenLab makes devices that process a patient's own blood for regenerative medicine, such as platelet-rich plasma. Founded in Switzerland, it now has a U.S. holding company and sites in New Jersey, Paris and Monthey (Switzerland).
It holds over 70 granted patents.
Fiscal year
Fiscal year
Fiscal year
Share of voting power held by the founders or controlling holders after the offering, as stated in the filing.
| $ | FY2024 | FY2025 | YoY |
|---|---|---|---|
| Revenue | 48.4M | 49.2M | +1.6% |
| Operating result | 3.48M | 675K | −80.6% |
| Net result | 2.31M | (1.24M) | n/m |
Values as filed, shortened (K = thousand, M = million, B = billion); losses in parentheses. Change columns compare each period with the same period a year earlier; a bigger loss shows as a negative change. Green is better for the company, red worse; n/m where the sign flips.
In plain English, from the filing's risk factors.
In plain English, from the filing's strategy section.
Source: Regenlab USA Inc.'s Form S-1/A, filed with the SEC on Oct 27, 2026 (preliminary prospectus). Figures are as filed; changes are worked out from them. Not investment advice.
Pinch-zoom for details.
10KDecoder (10-K Decoder): decode SEC 10-K filings and IPO prospectuses into dashboards and infographics.
Infographic
Double-tap: full screen or back